SCHEMBL566150

SCHEMBL566150

NC(=O)c1ccc2cccnc2n1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.71
LMNA P02545 2/20 0.71
MEN1 O00255 1/20 0.71
KMT2A Q03164 1/20 0.71
PIM1 P11309 2/20 0.50
ALDH1A1 P00352 2/20 0.49
PARP1 P09874 2/20 0.47
LCK P06239 1/20 0.42
DPP4 P27487 1/20 0.42
DPP9 Q86TI2 1/20 0.42
TSHR P16473 2/20 0.39
GMNN O75496 1/20 0.39
TP53 P04637 1/20 0.39
HSP90AA1 P07900 1/20 0.39
MMP2 P08253 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
MAPT P10636 1/20 0.39
MMP9 P14780 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30576393 1.00 KDM4E (0.71) KDM4ELMNAMEN1KMT2APIM1
Hydrochloric Acid SCHEMBL27739682 0.98 KDM4E (0.69) KDM4ELMNAMEN1KMT2APIM1
SCHEMBL6529041 0.85 KDM4E (0.76) KDM4ELMNAMEN1KMT2AALDH1A1
SCHEMBL30505600 0.83 KDM4E (1.00) KDM4ELMNAMEN1KMT2AALDH1A1
SCHEMBL30381290 0.83 KDM4E (1.00) KDM4ELMNAMEN1KMT2AALDH1A1
SCHEMBL2887500 0.83 KDM4E (0.73) KDM4ELMNAMEN1KMT2AALDH1A1
SCHEMBL125654 0.83 KDM4E (1.00) KDM4ELMNAMEN1KMT2AALDH1A1
Benzamide SCHEMBL27821964 0.82 KMT2A (0.77) KDM4ELMNAMEN1KMT2AALDH1A1
SCHEMBL123373 0.81 KDM4E (0.71) KDM4ELMNAMEN1KMT2AALDH1A1
Fluoride SCHEMBL28821496 0.81 KDM4E (0.96) KDM4ELMNAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119751447-A Asymmetric catalytic synthesis method of naphthyridine formamide medicament 上海彩迩文生化科技有限公司 2025-04-04 CN claimed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US claimed
CN-109952302-B Positive allosteric modulators of muscarinic M1 receptors 苏文生命科学有限公司 2020-11-24 CN claimed
WO-2020021300-A1 USE OF MYELOPEROXIDASE (MPO) INHIBITORS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-01-30 WO claimed
CN-109952302-A Muscarine M1 receptor forward direction allosteric modulators 苏文生命科学有限公司 2019-06-28 CN claimed
EP-2928470-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS Siga Technologies, Inc. (US) 2015-10-14 EP claimed
CN-103183676-B A group of 1-substituted-1, 8-naphthyridine formamide derivatives and preparation and application thereof INST MED BIOTECHNOLOGY CAMS 2015-04-08 CN claimed
CN-103957910-A Compounds and methods for enhancing innate immune responses GLAXOSMITHKLINE LLC 2014-07-30 CN claimed
WO-2014089378-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2014-06-12 WO claimed
EP-2723717-A2 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS Amgen Inc. (US) 2014-04-30 EP claimed
WO-2012177893-A2 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2012-12-27 WO claimed
US-20100291606-A1 SCREENING SYSTEM FOR DETECTING INHIBITORS OF HIV INTEGRASE-LEDGF/p-75 INTERACTION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-11-18 US claimed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US claimed
US-20060116368-A1 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-01 US claimed
WO-2006058338-A2 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-01 WO claimed
CN-119751447-B Asymmetric catalytic synthesis method of naphthyridine formamide medicament 上海彩迩文生化科技有限公司 2025-10-14 CN disclosed
CN-119751447-B Asymmetric catalytic synthesis method of naphthyridine formamide medicament 上海彩迩文生化科技有限公司 2025-10-14 CN disclosed
US-6143760-A Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands NEUROGEN CORPORATION (US) 2000-11-07 US disclosed
EP-1007526-A1 SUBSTITUTED 4-OXO-NAPTHYRIDINE-3-CARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2000-06-14 EP disclosed
WO-1999010347-A1 SUBSTITUTED 4-OXO-NAPTHYRIDINE-3-CARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 1999-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 KDM4E 403/4885LMNA 3132/4885MEN1 3554/4885
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 KDM4E 1855/4885LMNA 2545/4885MEN1 1111/4885
US-20060116368-A1 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor VDAC1, TRPV1, HVCN1 KDM4E 2664/4885LMNA 3237/4885MEN1 4809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.